HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...
HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II...
--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Of...
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chine...
--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivota...
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled p...
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled p...
HANGZHOU, China and SHAOXING, China, Nov. 29, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and m...
--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval...
--Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food ...
HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Asclet...
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin lik...
--ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Dru...
--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60...
-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroi...
-- After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China Na...
HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...
-- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhib...
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study...